Biotoxtech's earnings have been declining at an average annual rate of -46.5%, while the Life Sciences industry saw earnings declining at 3.1% annually. Revenues have been growing at an average rate of 8.8% per year.
How Biotoxtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A086040 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
47,636
769
10,391
667
31 Dec 25
47,017
1,163
10,248
643
30 Sep 25
44,190
879
9,227
546
30 Jun 25
43,411
-5,828
9,568
622
31 Mar 25
43,601
-6,612
9,996
927
31 Dec 24
41,341
-6,427
9,623
694
30 Sep 24
38,445
-4,410
9,859
760
30 Jun 24
34,475
-4,943
9,311
529
31 Mar 24
33,604
-5,419
8,638
273
31 Dec 23
32,631
-4,878
9,042
454
30 Sep 23
34,216
-5,408
10,241
332
30 Jun 23
36,638
-2,487
10,434
332
31 Mar 23
37,006
199
10,682
72
31 Dec 22
37,292
1,278
10,833
0
30 Sep 22
36,263
5,684
8,417
0
30 Jun 22
35,461
5,910
7,567
0
31 Mar 22
33,976
6,462
6,425
0
31 Dec 21
32,717
6,832
5,464
0
30 Sep 21
31,120
3,526
5,116
0
30 Jun 21
28,570
2,633
5,135
0
31 Mar 21
27,289
3,550
5,724
0
31 Dec 20
26,429
2,614
5,413
0
30 Sep 20
26,306
4,237
5,135
0
30 Jun 20
25,967
2,426
5,358
0
31 Mar 20
25,679
-1,414
5,086
0
31 Dec 19
25,854
-1,482
5,056
0
30 Sep 19
22,105
-4,913
2,770
-153
30 Jun 19
23,979
-1,548
3,526
-153
31 Mar 19
26,632
24
4,829
-88
31 Dec 18
27,245
4,131
5,100
0
30 Sep 18
31,567
5,261
9,270
235
30 Jun 18
29,985
3,735
8,541
235
31 Mar 18
27,059
4,887
7,065
170
31 Dec 17
25,565
1,392
6,297
83
30 Sep 17
24,330
2,115
4,795
0
30 Jun 17
23,992
1,966
4,560
0
31 Mar 17
23,196
1,584
4,468
0
31 Dec 16
22,257
1,045
4,915
0
30 Sep 16
20,404
-1,173
6,225
-10
30 Jun 16
18,932
-1,942
6,051
2
31 Mar 16
17,932
-2,873
6,349
12
31 Dec 15
16,676
-3,905
6,438
23
30 Sep 15
15,384
-3,790
5,280
31
Quality Earnings: A086040 has a large one-off gain of ₩7.8B impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: A086040 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086040's earnings have declined by 46.5% per year over the past 5 years.
Accelerating Growth: A086040 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A086040 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-26.7%).
Return on Equity
High ROE: A086040's Return on Equity (-7.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/06 11:19
End of Day Share Price
2026/07/06 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotoxtech Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.